Mudanças no cenário do tratamento da tuberculose durante a pandemia da Covid-19 no Brasil
Tipo
TCC
Data de publicação
2024-06-20
Periódico
Citações (Scopus)
Autores
Rocha, Guilherme Tardoski
Pereira, João Vitor Flores
Pereira, João Vitor Flores
Orientador
Rossoni, Andrea Maciel de Oliveira
Título da Revista
ISSN da Revista
Título de Volume
Membros da banca
Programa
Resumo
INTRODUÇÃO: A infecção latente da tuberculose (ILTB) é uma doença que pode ser tratada visando sua não reativação. O perfil do paciente, bem como outras particularidades do tratamento podem ter alterado no período da pandemia COVID-19 devido a seu impacto social. OBJETIVO: Avaliar diferenças nos quadros de pacientes sendo tratados preventivamente pela tuberculose no decorrer da pandemia.MÉTODOS:Será um estudo descritivo, analítico, transversal e retrospectivo. Os dados serão obtidos através da análise do banco de dados de notificação da ILTB do Ministério da Saúde no período de 2020 a 2022. RESULTADOS: Foram avaliados 91.340 fichas de notificação que se distribuíram ao de maneira crescente ao longo dos anos, sendo composta majoritariamente por mulheres e com uma média de idade de 36,38 anos. Houve no ano de 2021 a adição de mais um esquema terapêutico para o manejo da ILTB (isoniazida associado a rifapentina), que apresentou maior taxa de adesão. Também é notado maior porcentagem de situação de encerramento completo no grupo raça/cor “indígena” em relação aos demais. Quanto às indicações para o tratamento da ILTB, elas mantiveram uma constância ao longo do período analisado. CONCLUSÃO: Houve uma taxa de maior adesão no tratamento de isoniazida associado a rifapentina em relação aos demais, evidente na população indígena.
INTRODUCTION: Latent tuberculosis infection (LTBI) is a disease treatable with the intention of preventing reactivation. Patient profile, as well as other treatment characteristics may have shifted during the COVID-19 pandemic due to its societal impact. OBJECTIVE: Evaluate differences in the outlook of patients being preventively treated for tuberculosis throughout the pandemic. MATERIAL AND METHODS: A descriptive, analytical, retrospective transverse study was performed, with data being obtained via statistical analysis of the LTBI notification database from the Brazilian Ministry of Health from 2020 through 2022. RESULTS: The 91.340 notifications analyzed displayed themselves increasingly over the years, being mostly composed of women and displaying an average age of 36.38 years. In the year 2021, a new treatment option for LTBI was made available (rifapentine isoniazid association) and showed higher treatment adherence. Also noted is the higher treatment completion rate in the ethnic group “Indigenous” when compared to other groups. As to LTBI treatment indications, mostly consistency was observed during the selected period. CONCLUSION: The association between isoniazid and rifapentine displayed higher treatment adherence rates, as observed in the indigenous population.
INTRODUCTION: Latent tuberculosis infection (LTBI) is a disease treatable with the intention of preventing reactivation. Patient profile, as well as other treatment characteristics may have shifted during the COVID-19 pandemic due to its societal impact. OBJECTIVE: Evaluate differences in the outlook of patients being preventively treated for tuberculosis throughout the pandemic. MATERIAL AND METHODS: A descriptive, analytical, retrospective transverse study was performed, with data being obtained via statistical analysis of the LTBI notification database from the Brazilian Ministry of Health from 2020 through 2022. RESULTS: The 91.340 notifications analyzed displayed themselves increasingly over the years, being mostly composed of women and displaying an average age of 36.38 years. In the year 2021, a new treatment option for LTBI was made available (rifapentine isoniazid association) and showed higher treatment adherence. Also noted is the higher treatment completion rate in the ethnic group “Indigenous” when compared to other groups. As to LTBI treatment indications, mostly consistency was observed during the selected period. CONCLUSION: The association between isoniazid and rifapentine displayed higher treatment adherence rates, as observed in the indigenous population.
Descrição
Palavras-chave
pandemia COVID 19 , tuberculose latente , medidas em epidemiologia , COVID-19 pandemic , epidemiologic measurements , latent tuberculosis